Tree

Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options

Format

GLB

Size

6.6 MB

Ready

W × H × D

3.6 x 3.8 x 3.5 cm

≈ coin (3.0 cm)

Screenshots

Include QR code and name Background

Screenshots will be available when the model finishes loading.

Video recording

Record a WebM/MP4 clip of the interactive canvas.

Color

Custom colour

Preview only — the color isn’t saved.

Background

Preview rotation

X Y Z

Publication metadata

Publication Info

Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options

Authors: Vincenzi Bruno, Frezza Anna Maria, Schiavon Gaia

Year: 2013

Field: Medicine

Institution: Clinical Sarcoma Research

DOI: 10.1186/2045-3329-3-6

Description / Abstract

Abstract Background We surveyed the natural history of bone metastases in patients affected by soft tissue sarcoma (STS). Methods This multicenter retrospective observational study included 135 patients. Histological subtype, characteristics of bone metastases, treatment, skeletal related events (SREs) and disease outcome were recorded. Results The most represented histological subtypes were leiomyosarcoma (27%) angiosarcoma (13%) and undifferentiated sarcoma (8%). Axial skeleton was the most common site for bone involvement (70%). In 27% of cases, bone metastases were present at the time of diagnosis. Fifty-four (40%) patients developed SREs and the median time to first SRE was 4 months (range 1–9). The most common SRE was the need for radiotherapy (28%) followed by pathological fracture (22%). Median survival after bone progression was 6 months (range 1–14). SREs were associated with decreased overall survival (OS) (P = 0.04). A subgroup analysis revealed that bisphosphonates significantly prolonged median time to first SRE (5 versus 2 months; P = 0.002) while they did not determine an improvement in OS, although a favourable trend was identified (median: 7 versus 5 months; P = 0.105). Conclusions This study illustrates the burden of bone disease from STS and supports the use of bisphosphonates in this setting.

Model Note

tree model

Tree

Scan for AR

View

Build a combined figure